Intraocular Pressure

WASHINGTON — Patients with advanced open-angle glaucoma experienced a sustained IOP and medication reduction after undergoing cyclophotocoagulation combined with trabecular meshwork bypass MIGS, according to the co-author of a poster here.

Durysta, the first intracameral biodegradable sustained-release implant designed to lower IOP in patients with open-angle glaucoma or ocular hypertension, has been approved by the FDA, Allergan announced in a press release.

Working on a smartphone in low-light conditions can induce elevated IOP in patients with normal tension glaucoma, according to findings published in the British Journal of Ophthalmology.

Minimally invasive glaucoma surgery techniques have been an invaluable addition to the armamentarium of glaucoma management. Many options are currently available, but there are no hard and fast guidelines for surgeons to choose between options.

Secondary angle closure due to any mechanism compromises the normal aqueous outflow route and results in secondary elevation of IOP. Left uncorrected, over time this can cause optic nerve damage and possible permanent vision loss. When medical avenues are ineffective in opening the angle, surgical intervention to either open the closed angle or provide an alternate route of aqueous egress is essential to prevent potential vision loss.

A 77-year-old man presented to the Lahey Medical Center emergency department with a chief complaint of right eye vision loss for several hours.

Aerie Pharmaceuticals has submitted a marketing authorization application for Roclanda to the European Medicines Agency, according to a press release.

Ocuphire Pharma Inc. will prioritize the development of Nyxol eye drops for three indications following positive topline results from two phase 2 studies, the company announced.

A Japanese phase 2 clinical study of netarsudil ophthalmic solution showed a significant reduction in mean intraocular pressure compared with placebo, Aerie Pharmaceuticals announced in a press release.

The German state of Saxony has granted a $7.5 million grant to Mannin, a technology partner of Q BioMed Inc., to develop novel pharmaceuticals and biologic treatments for glaucoma, according to a press release.